Expertise in
2
conditions

Olusola O. Faluyi

Liverpool, ENG, GB 
Expertise in
2
conditions
Liverpool, ENG, GB 

Overview

Olusola Faluyi practices practicing medicine in Liverpool, United Kingdom.

Faluyi is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Neuroendocrine Tumor, Esophageal Cancer, Pancreatic Cancer, and Familial Adenomatous Polyposis.

They are actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 2 clinical trials.

Locations

Liverpool, ENG, United Kingdom
Other Locations
Wirral, ENG, United Kingdom
United Kingdom
Edinburgh, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

20 Total Publications

ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.
Journal: Future oncology (London, England)
Published: July 29, 2025

Frequently Asked Questions about Olusola O. Faluyi

Is Olusola O. Faluyi a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Olusola O. Faluyi is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olusola O. Faluyi participate in research or clinical trials?

Yes. Olusola O. Faluyi has published 20 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Olusola O. Faluyi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Faluyi's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile